A new drug may slow Alzheimer's disease
Experts have described as a historical moment the drug that was effective in slowing down Alzheimer's disease.
Pharmaceutical companies Eisai and Biogen have said the drug works when given in the early stages of the disease. Full details have not yet been released, but it appears that the proposed drug slows the rate of brain decline.
It is the drug lecanemab, designed to remove clumps of toxic beta-amyloid protein from the brains of people with Alzheimer's disease.
In a trial that tested more than 1,795 volunteers in the early stages of Alzheimer's disease who were injected with lecanemab every two weeks, the rate of cognitive decline was reduced by 27%, compared to sufferers treated with currently used drugs for the cure of this disease, dummy and placebo, said the pharmaceutical companies. They also showed that levels of the toxic protein were decreased in the brain.
Biogen Chief Executive Michel Vounatsos said this gives patients and their families hope that lecanemab, if approved, could slow the progression of Alzheimer's disease.